XFORX4 Pharmaceuticals, Inc同业对比
X4 Pharmaceuticals, Inc 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XFOR本股 | $349M#8 | 2.5x#2 | 2.2x#9 | 10.0x#3 | 1273.2%#2 | -111.5%#16 | -247.4%#3 | -50.9%#10 | -582.0%#4 | — | 9.1%#10 | — |
| ZURA | $444M#2 | — | 4.4x#13 | — | — | -31.0%#11 | — | -67.6%#11 | — | — | 137.4%#4 | — |
| KYTX | $427M#3 | — | 2.6x#11 | — | — | -26.5%#9 | — | -97.4%#13 | -107.1%#3 | — | 77.2%#5 | — |
| CCCC | $424M#4 | — | 1.7x#5 | 11.8x#5 | 1.0%#6 | 0.3%#5 | -320.5%#4 | -42.5%#8 | — | — | 1.3%#11 | — |
| CABA | $420M#5 | — | 2.0x#7 | — | — | -44.9%#13 | — | -79.7%#12 | — | — | 24.9%#9 | — |
| ARTV | $420M#6 | — | 1.2x#1 | — | -100.0%#7 | -28.3%#10 | — | -24.1%#5 | — | — | 262.7%#2 | — |
| EDIT | $418M#7 | — | 4.0x#12 | 10.3x#4 | 25.4%#3 | 32.5%#4 | -394.9%#5 | -152.0%#14 | — | — | -3.9%#12 | — |
| GRML | $477M#1 | — | 8.2x#14 | — | — | -71.6%#14 | — | -18.2%#4 | -14.6%#2 | — | -89.7%#16 | — |
| OCGN | $344M#9 | — | — | 78.0x#6 | 8.8%#5 | -25.9%#8 | -1425.7%#6 | — | — | — | -12.9%#13 | — |
| LXEO | $342M#10 | — | 1.5x#3 | 523.1x#7 | — | -1.7%#6 | -16706.0%#7 | -42.5%#9 | — | — | -19.9%#14 | — |
| IPSC | $340M#11 | — | 1.5x#4 | 3.1x#2 | 1556.8%#1 | 92.4%#3 | -15.8%#1 | -4.1%#2 | -9.3%#1 | — | 286.4%#1 | — |
| CMPX | $330M#12 | — | 2.0x#6 | — | -100.0%#7 | -34.7%#12 | — | -40.0%#7 | — | — | -49.2%#15 | — |
| AGEN | $325M#13 | 2.4x#1 | — | 2.8x#1 | 10.4%#4 | 98.7%#2 | -17.7%#2 | — | — | — | 61.5%#6 | — |
| IKT | $322M#14 | — | 2.1x#8 | — | -100.0%#7 | -75.4%#15 | — | -31.5%#6 | — | — | 48.1%#8 | — |
| SABS | $308M#15 | 14.1x#4 | 1.4x#2 | — | -100.0%#7 | 138.9%#1 | — | 6.2%#1 | — | — | 61.2%#7 | — |
| PALI | $293M#16 | 2.6x#3 | 2.4x#10 | — | — | -16.2%#7 | — | -13.8%#3 | — | — | 179.4%#3 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议